4.JPG)
The Live Biotherapeutic Products And Microbiome Contract Manufacturing Market Size is valued at 141.52 Million in 2023 and is predicted to reach 993.81 Million by the year 2031 at a 23.19 % CAGR during the forecast period for 2024-2031.
Key Industry Insights & Findings from the Report:
- Increasing R&D activities aimed at redefining the development of next-generation live biotherapeutic and microbiome contract manufacturing market
- Increased incidence of cancer, autoimmune disorders, and infectious diseases. Moreover, the growing demand for highly effective medicines, drugs, and cancer therapies substantiates the market growth
- High investment by government and public entities. There has been a paradigm shift over the past few years from traditional chemotherapy to biotherapy, which is propelling the overall market.
- North America dominated the market and accounted for a revenue share of global revenue in 2023
- However, Lack of industry standards and regulatory framework is anticipated to affect the market growth
The Human Microbiome is the group of loads of microbes living on and in the human body. The microbiomes are found, for example, in the skin, gut, mouth, and vagina. A live biotherapeutic product comprises a live microorganism used for the cure or treatment and prevention of disease. The live biotherapeutic industry is experiencing enormous research and development activities to develop products for various diseases and applications.
Till now, about 200 companies are developing microbiome-based therapies anticipated to treat an extensive range of severe diseases, with big pharmaceutical companies showing augmented interest by associating with early innovators. Most of the clinical treatment is under the preclinical stage, various are under clinical development, and about 15 are in phase II/III trials of development. The commercialization of these products in the coming years is expected to generate a huge potential for the growth of the market over the estimated timeframe. However, the lack of a satisfactory manufacturing capacity of the innovators may significantly hinder the market's growth. Additionally, lack of the essential industry standards associated with live biotherapeutics manufacturing, batch-to-batch reliability-related concerns, lack of infrastructure, and uncertainties related to product approval and regulatory review are some of the factors affecting market growth substantially. However, a growing number of deals among various developers for contract manufacturing is projected to generate immense opportunities for the market's growth globally.
Market Segmentation
The Global Live Biotherapeutic Products and Microbiome Contract Manufacturing Market is segmented on the basis of type of services, the scale of operation, and application. Based on the type of services, the market is segmented into Development Services, Manufacturing Services, and Others (Regulatory expertise and support, Quality Control and Assurance). Based on the scale of operation, the market is categorized into, preclinical scale operations, clinical scale operations, and commercial-scale operations. Also, in case of applications segment it is catagorised as C.difficle, Crohns disease, IBS, Diabetes and Others. Based on the region, the market is studied across North America, Asia-Pacific, Europe, and LAMEA.
Competitive Landscape
Some major key players in the Live Biotherapeutic Products And Microbiome Contract Manufacturing Market:
- Quay Pharmaceuticals,
- Cerbios-Pharma SA,
- List Biological Labs, Inc.,
- Arranta Bio (Acquired by Recipharm),
- BacThera,
- Biose Industrie
- Wacker Biotech,
- Other prominent players
Live Biotherapeutic Products And Microbiome Contract Manufacturing Market Report Scope
|
Report Attribute |
Specifications |
|
Market Size Value In 2023 |
USD 141.52 Million |
|
Revenue Forecast In 2031 |
USD 993.81 Million |
|
Growth Rate CAGR |
CAGR of 23.19 % from 2024 to 2031 |
|
Quantitative Units |
Representation of revenue in US$ Million and CAGR from 2024 to 2031 |
|
Historic Year |
2019 to 2023 |
|
Forecast Year |
2024-2031 |
|
Report Coverage |
The forecast of revenue, the position of the company, the competitive market structure, growth prospects, and trends |
|
Segments Covered |
By Type of Services, Scale of operations, Application |
|
Regional Scope |
North America; Europe; Asia Pacific; Latin America; Middle East & Africa |
|
Country Scope |
U.S.; Canada; U.K.; Germany; China; India; Japan; Brazil; Mexico ;The UK; France; Italy; Spain; China; Japan; India; South Korea; South East Asia; South Korea; South East Asia |
|
Competitive Landscape |
Quay Pharmaceuticals, Cerbios-Pharma SA, List Biological Labs, Inc., Arranta Bio (Acquired by Recipharm), BacThera, Wacker Biotech, Biose Industrie, Wacker Biotech and Other prominent players |
|
Customization Scope |
Free customization report with the procurement of the report, Modifications to the regional and segment scope. Particular Geographic competitive landscape. |
|
Pricing And Available Payment Methods |
Explore pricing alternatives that are customized to your particular study requirements. |
Corporate
Office :
Office No.5170, 5th Floor Marvel Fuego, Magarpatta Rd, Pune, 411028
info@insightaceanalytic.com
